EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​

Xiaoyu Zhang, Yanhong Zhao, Weihua Zhai, Qiaoling Ma, Yigeng Cao, Jialin Wei, Chen Liang, Xin Chen, Wenbin Cao, Donglin Yang, Aiming Pang, Yi He und 4 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06708-0 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Annals of Hematology, 2025. Verfasst von Xiaoyu Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clin…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olverembatinib is a novel third-generation TKI available in mainland China. However, there are only a few published clinical reports. In this study, we aimed to investigate the efficacy and safety of an olverembatinib-venetoclax regimen before bridging to HSCT in adult Ph/BCR-ABL1 + ALL patients with refractory/relapsed disease (n = 2) or persistent minimal residual disease (MRD) (n = 15). Seventeen Ph + ALL patients who were admitted to our center between February 2022 and January 2023 were enrolled. Four patients harbored a T315I mutation. In all, 100% achieved hematologic complete remission, and 70.6% achieved complete molecular remission. With a median follow-up of 856-day post-HSCT, the 2-year overall survival and relapsed free survival rates was 88.2 ± 7.8% and 79.4 ± 10.9%, respectively. The findings of this study suggest that in Ph + ALL patients with disease recurrence and persistent MRD positivity, olverembatinib-venetoclax regimen showed a high molecular response rate and was well-tolerated in MRD clearance bridged to allo-HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansAdultFemaleMaleMiddle AgedNeoplasm, ResidualRecurrenceYoung AdultFusion Proteins, bcr-ablTreatment OutcomePhiladelphia ChromosomeProtein Kinase InhibitorsAdolescentPyrimidines

Stichwörter der Autor:innen

Allo-HSCTComplete molecular remissionOlverembatinibPh + ALLVenetoclax

Substanzen

SulfonamidesFusion Proteins, bcr-ablProtein Kinase InhibitorsPyrimidines

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, 301600, China.
  • Tianjin Institutes of Health Science, Tianjin, 301600, China. zhangrongli@ihcams.ac.cn.
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300060, China. zhangrongli@ihcams.ac.cn.
  • Tianjin Institutes of Health Science, Tianjin, 301600, China. jiangerlie@ihcams.ac.cn.
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300060, China. jiangerlie@ihcams.ac.cn.

Zitieren

APA

Zhang, X., Zhao, Y., Zhai, W., Ma, Q., Cao, Y., Wei, J., Liang, C., Chen, X., Cao, W., Yang, D., Pang, A., He, Y., Feng, S., Han, M., Zhang, R., & Jiang, E. (2025). Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​. Annals of Hematology. https://doi.org/10.1007/s00277-025-06708-0

Vancouver

Zhang X, Zhao Y, Zhai W, Ma Q, Cao Y, Wei J, et al. Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​. Annals of Hematology. 2025. doi:10.1007/s00277-025-06708-0

BibTeX
@article{Zhang2025,
  author = {Zhang, Xiaoyu and Zhao, Yanhong and Zhai, Weihua and Ma, Qiaoling and Cao, Yigeng and Wei, Jialin and Liang, Chen and Chen, Xin and Cao, Wenbin and Yang, Donglin and Pang, Aiming and He, Yi and Feng, Sizhou and Han, Mingzhe and Zhang, Rongli and Jiang, Erlie},
  title = {Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06708-0}
}
Kostenlos starten →